Single Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysis
药物诱导史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症中致病性 T 细胞的单细胞定义
基本信息
- 批准号:9574331
- 负责人:
- 金额:$ 23.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-22 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute DiseaseAddressAllelesAllopurinolAntigensBiological AssayBullaBurn injuryCD3 AntigensCD8-Positive T-LymphocytesCD8B1 geneCarbamazepineCellsCessation of lifeClinicalClonal ExpansionClonalityDataDevelopmentDiseaseDrug DesignEarly DiagnosisEarly identificationEmergency SituationEtiologyExclusionExposure toFire - disastersFlow CytometryFoundationsFutureGenetic ScreeningGenetic TranscriptionHLA-B AntigensHealth Care CostsHomingImmuneImmunologicsImmunophenotypingIncidenceIndividualKnowledgeLaboratoriesLeadLifeLinkLiquid substanceMediatingMediator of activation proteinModelingMolecular ProfilingMorbidity - disease rateMucous MembraneNCAM1 geneNatural Killer CellsNecrosisOutcomePathogenesisPathogenicityPathologicPathologyPatientsPeptidesPharmaceutical PreparationsPhasePhenotypePopulationPredictive ValuePreventionProcessReactionResearchResolutionRiskSamplingSeveritiesSiteSkinSorting - Cell MovementSoutheastern AsiaStevens-Johnson SyndromeSupportive careT memory cellT-Cell ActivationT-Cell ReceptorT-LymphocyteT-cell receptor repertoireTestingThickToxic Epidermal NecrolysisUncertaintyUnited Statesbiobankcost effectivecytotoxicdesigndisabilitydrug developmentgranulysinhuman leukocyte antigen testingindexinginsightkeratinocytemolecular markermortalitymultiple omicsneoantigensnovel strategiesnovel therapeutic interventionoutcome forecastpeptide drugrecruitresidencerisk variantscreeningscreening programtargeted treatmenttherapeutic targettranscriptome sequencingtranscriptomics
项目摘要
PROJECT SUMMARY
Drug-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the severest
of immunologically-mediated adverse drug reactions (IM-ADR) associated with blistering, mucosal sloughing
and epidermal necrosis. The mortality, personal disability and healthcare costs of SJS/TEN are out of proportion
to its incidence of 5 cases per 1,000,000/year in the United States. Genetic screening with drug-specific HLA
risk alleles has 100% negative predictive value and is cost-effective in some settings, however, only 2-8% of
individuals carrying a drug-specific HLA risk allele when exposed to the relevant drug develop SJS/TEN. Strong
HLA class I associations, the presence of granulysin-producing CD8+ T cells in the SJS/TEN blister fluid,
and the critical need to understand what factors in addition to the HLA risk allele are necessary for
development of SJS/TEN form the scientific premise and significance of this study. Using our extensive
existing biobank of cryopreserved blister fluid samples from patients with rigorously phenotyped acute drug-
induced SJS/TEN, and blister cells from patients with fire and scald partial thickness burns as non-antigen driven
controls we will use an integrated multi-omic approach to define at a single-cell level the antigen-driven CD8+ T
cells at the site of pathology of SJS/TEN and their transcriptomic signatures.
In Specific Aim 1 we will use bulk and single cell T-cell receptor (TCR) sequencing approaches to
quantify the TCR clonality of activated CD8+ T cells in the blister fluid of acute SJS/TEN patients. Our
hypothesis is that the drug antigen drives recruitment and/or clonal expansion of activated CD8+ T cells
with specific T-cell receptor(s) (TCR) that will be enriched in blister fluid during acute disease. In some
cases the dominant TCR clonotype, may be shared amongst unrelated individuals with the same HLA-risk allele.
Single live T cells from blister fluid will be sorted according to activated (CD3+CD8+CD137+) and non-activated
(CD3+CD8+CD137-) profile and subjected to TCR repertoire sequencing. In Specific Aim 2 we will define the
transcriptomic signatures of activated CD8+ T cells in the blister fluid of patients with acute SJS/TEN.
RNA-seq profiling of single cells from blister fluid will be combined with index sorting data from multi-parameter
flow cytometry panels that will enable us to identify transcriptomic signatures associated with potentially
expanded antigen-driven TCR clonotypes. Our hypothesis is that the CD8+ T cells in blister fluid will have
an expression phenotype that includes granulysin and other cytolytic mediators, and early activation
markers such as CD137.
We will use novel approaches to link the pathogenic T-cell receptor clonotypes and their phenotypic
signatures. This will provide important insights into the immunopathogenesis of HLA class I restricted, drug-
induced SJS/TEN to fuel prevention, early diagnosis and identification of rationale therapeutic targets. It will also
provide a roadmap for single cell studies applicable to other severe immunologically mediated diseases.
项目摘要
药物引起的Stevens-Johnson综合征(SJS)和中毒性表皮坏死松解症(TEN)是最常见的
免疫介导的药物不良反应(IM-ADR)与水疱、粘膜脱落
和表皮坏死。SJS/TEN的死亡率、个人残疾和医疗费用不成比例
在美国,其发病率为5例/1,000,000/年。药物特异性HLA基因筛查
风险等位基因具有100%的阴性预测值,并且在某些情况下具有成本效益,然而,只有2-8%的
携带药物特异性HLA风险等位基因的个体在暴露于相关药物时发生SJS/TEN。强
HLA I类相关性,SJS/TEN水疱液中存在产生颗粒溶解素的CD 8 + T细胞,
以及迫切需要了解除了HLA风险等位基因之外,
SJS/TEN的发展构成了本研究的科学前提和意义。利用我们广泛的
现有的生物样本库中,冷冻保存的水疱液样本来自于具有严格表型的急性药物依赖的患者,
诱导的SJS/TEN和来自火烧伤和深Ⅱ度烧伤患者的水疱细胞作为非抗原驱动的
对照组,我们将使用整合的多组学方法在单细胞水平上定义抗原驱动的CD 8 + T细胞。
SJS/TEN病理部位的细胞及其转录组学特征。
在具体目标1中,我们将使用批量和单细胞T细胞受体(TCR)测序方法,
定量急性SJS/TEN患者水疱液中活化的CD 8 + T细胞的TCR克隆性。我们
假设药物抗原驱动活化的CD 8 + T细胞的募集和/或克隆扩增
具有在急性疾病期间将在水疱液中富集的特异性T细胞受体(TCR)。在一些
在某些情况下,显性TCR克隆型可能在具有相同HLA风险等位基因的无关个体之间共享。
将根据活化(CD 3 + CD 8 + CD 137+)和非活化(CD 137+)对来自水疱液的单个活T细胞进行分选。
(CD3+ CD 8 + CD 137-)谱,并进行TCR库测序。在具体目标2中,我们将定义
急性SJS/TEN患者水疱液中活化CD 8 + T细胞的转录组学特征。
来自疱液的单细胞的RNA-seq分析将与来自多参数的索引分选数据相结合
流式细胞仪面板,这将使我们能够识别与潜在的
扩增的抗原驱动的TCR克隆型。我们的假设是,水疱液中的CD 8 + T细胞将具有
表达表型,包括颗粒溶解素和其他细胞溶解介质,以及早期激活
如CD 137。
我们将使用新的方法将致病性T细胞受体克隆型和它们的表型
签名.这将为HLA I类限制性、药物性和非药物性的免疫发病机制提供重要的见解。
诱导的SJS/TEN有助于预防、早期诊断和确定合理的治疗靶点。它还将
为适用于其他严重免疫介导疾病的单细胞研究提供路线图。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Phillips其他文献
Elizabeth Phillips的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth Phillips', 18)}}的其他基金
Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) 2023
史蒂文斯约翰逊综合症/中毒性表皮坏死松解症 (SJS/TEN) 2023
- 批准号:
10682795 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NATIENS:一项 III 期随机双盲研究,以确定史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的机制和最佳治疗
- 批准号:
10217036 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NATIENS:一项 III 期随机双盲研究,以确定史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的机制和最佳治疗
- 批准号:
10402818 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
NATIENS:一项 III 期随机双盲研究,以确定史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的机制和最佳治疗
- 批准号:
10612063 - 财政年份:2020
- 资助金额:
$ 23.7万 - 项目类别:
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
幸存者中药物引起的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症相关的遗传风险和长期结果
- 批准号:
10214660 - 财政年份:2019
- 资助金额:
$ 23.7万 - 项目类别:
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
幸存者中药物引起的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症相关的遗传风险和长期结果
- 批准号:
10441271 - 财政年份:2019
- 资助金额:
$ 23.7万 - 项目类别:
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors
幸存者中药物引起的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症相关的遗传风险和长期结果
- 批准号:
10018069 - 财政年份:2019
- 资助金额:
$ 23.7万 - 项目类别:
Stevens-Johnson Syndrome/Toxic Epidural Necrolysis 2017: Building Multidisciplinary Networks to Drive Science and Translation
史蒂文斯-约翰逊综合症/中毒性硬膜外坏死松解术 2017:建立多学科网络以推动科学和翻译
- 批准号:
9261224 - 财政年份:2017
- 资助金额:
$ 23.7万 - 项目类别:
Understanding and preventing HLA-associated drug reactions
了解和预防 HLA 相关药物反应
- 批准号:
8934766 - 财政年份:
- 资助金额:
$ 23.7万 - 项目类别:
Understanding and preventing HLA-associated drug reactions
了解和预防 HLA 相关药物反应
- 批准号:
9100798 - 财政年份:
- 资助金额:
$ 23.7万 - 项目类别:
相似海外基金
Improving Acute Disease Management for Patients with Alzheimer's Disease and Related Dementias
改善阿尔茨海默病和相关痴呆症患者的急性疾病管理
- 批准号:
10712647 - 财政年份:2001
- 资助金额:
$ 23.7万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
6247642 - 财政年份:1997
- 资助金额:
$ 23.7万 - 项目类别:
INDUCTION OF ACUTE DISEASE IN MACAQUES BY NEF GENE VARIANT OF SIVMAC239
SIVMAC239 的 NEF 基因变体在猕猴中诱导急性疾病
- 批准号:
3718999 - 财政年份:
- 资助金额:
$ 23.7万 - 项目类别:
Neurophysiological alterations in multiple sclerosis patients during acute disease acivity
多发性硬化症患者急性疾病活动期间的神经生理学变化
- 批准号:
465668867 - 财政年份:
- 资助金额:
$ 23.7万 - 项目类别:
Research Grants
SIVMAC 1NEF ALLELE: LYMPHOCYTE ACTIVATION & ACUTE DISEASE IN MACAQUE MONKEYS
SIVMAC 1NEF 等位基因:淋巴细胞激活
- 批准号:
3719026 - 财政年份:
- 资助金额:
$ 23.7万 - 项目类别: